New
HealthMore in Health→
Lead-212 Therapy Shows Early Signals in Advanced Prostate Cancer
Key Takeaways
- Phase I trial enrolled 22 people with progressive advanced prostate cancer.
- No dose-limiting toxicities were observed in the reported study results.
- Eighty percent of participants had PSA declines of at least 50%.
- The treatment is investigational and requires larger clinical trials.
DE
DT Editorial Team··via medicalxpress.com
